2017

July 10: The Phase I clinical trial of recombinant human thymosin β4 for injection officially commences.

October: The recombinant human hepatocyte growth factor naked plasmid injection was approved for Phase III clinical trials.

December: The NL005 project has once again been approved as a key national special project for the development of new drugs.